Potočnjak Ines, Degoricija Vesna, Vukičević Baudoin Dina, Čulig Josip, Jakovljević Miro
University Hospital Center Sisters of Charity, Vinogradska cesta 29, 10000 Zagreb, Croatia.
University of Zagreb School of Medicine, Šalata 3, 10000 Zagreb, Croatia; University Hospital Center Sisters of Charity, Vinogradska cesta 29, 10000 Zagreb, Croatia.
Int J Cardiol. 2016 Sep 15;219:367-72. doi: 10.1016/j.ijcard.2016.06.057. Epub 2016 Jun 20.
WHO defined in 1976 psychopharmaca as drugs affecting psychological functions, behaviour and self-perception. Psychopharmacology is the study of pharmacological agents that affect mental and emotional functions. Creative approach to psychopharmacotherapy reflects a transdisciplinary, integrative and person-centered psychiatry. Psychiatric disorders often occur in cardiac patients and can affect the clinical presentation and morbidity. Cardiovascular (CV) side effects (SE) caused by psychopharmaceutic agents require comprehensive attention. Therapeutic approach can increase placebo and decrease nocebo reactions. The main purpose of this review is to comprehend CV SE of psychotropic drugs (PD). Critical overview of CV SE of PD will be presented in this review. Search was directed but not limited to CV effects of psychopharmacological substances, namely antipsychotics, anxiolytics, hypnotics, sedatives, antidepressants and stimulants. Literature review was performed and data identified by searches of Medline and PubMed for period from 2004 to 2015. Only full articles and abstracts published in English were included. SE of PD are organized according to the following types of CV effects: cardiac and circulatory effects, abnormalities of cardiac repolarisation and arrhythmias and heart muscle disease. There is wide spectrum and various CV effects of PD. Results of this review are based on literature research. The reviewed data came largely from prevalence studies, case reports, and cross-sectional studies. Psychopharmacotherapy of psychiatric disorders is complex and when concomitantly present with CV disease, presentation of drug SEs can significantly contribute to illness course. Further development of creative psychopharmacotherapy is required to deal with CV effects of PD.
世界卫生组织在1976年将精神药物定义为影响心理功能、行为和自我认知的药物。精神药理学是研究影响精神和情感功能的药物制剂的学科。精神药物治疗的创新方法反映了跨学科、综合且以患者为中心的精神病学。精神疾病常发生于心脏病患者中，并可影响临床表现和发病率。精神药物引起的心血管（CV）副作用需要全面关注。治疗方法可增加安慰剂效应并减少反安慰剂反应。本综述的主要目的是了解精神药物（PD）的心血管副作用。本综述将对精神药物的心血管副作用进行批判性概述。检索范围有针对性但不限于精神药物的心血管效应，即抗精神病药、抗焦虑药、催眠药、镇静剂、抗抑郁药和兴奋剂。进行了文献综述，并通过检索2004年至2015年期间的Medline和PubMed数据库来确定数据。仅纳入以英文发表的全文和摘要。精神药物的副作用根据以下心血管效应类型进行分类：心脏和循环系统效应、心脏复极异常和心律失常以及心肌疾病。精神药物具有广泛的心血管效应。本综述的结果基于文献研究。所审查的数据主要来自患病率研究、病例报告和横断面研究。精神疾病的精神药物治疗很复杂，当与心血管疾病同时存在时，药物副作用的表现可显著影响病程。需要进一步发展创新的精神药物治疗来应对精神药物的心血管效应。
